Where Will Walgreens Be in 1 Year?

Walgreens Boots Alliance (WBA) is being taken private by Sycamore Partners Management for $11.45 per share, a deal expected to close in the second half of 2025. Despite the agreed acquisition price, WBA shares are trading higher due to a unique provision: shareholders will receive a contingent value right (CVR) tied to the future sale of WBA's medical clinic business, potentially adding up to $3 per share. However, the CVR's ultimate value and payout timeline are uncertain, as there is no guaranteed sale price or schedule for the clinic divestiture, positioning WBA as a high-risk, special situations investment primarily for aggressive investors.

Analysis

Walgreens Boots Alliance (WBA) has entered a definitive agreement to be taken private by Sycamore Partners Management at a price of $11.45 per share, with the transaction expected to close in the second half of 2025. This M&A activity follows a period of significant operational underperformance, marked by failed growth initiatives in pharmacy benefits and healthcare clinics, market saturation, and the eventual elimination of its dividend. Uncharacteristically for an acquisition target, WBA's stock is trading above the deal price, an anomaly explained by a special provision in the transaction. Shareholders will receive a contingent value right (CVR) tied to the future sale of WBA's medical clinic business, which could yield an additional payout of up to $3 per share. However, this potential upside is highly speculative, as there is no guaranteed sale price for the clinic assets nor a defined timeline for their divestiture. Consequently, the CVR's ultimate value is uncertain and could be zero, positioning the stock as a high-risk special situation rather than a traditional merger arbitrage play.

Key Decisions for Investors

• Investors should recognize that purchasing WBA shares above the $11.45 acquisition price constitutes a direct and speculative bet on the value of the contingent value right, which has no guaranteed payout or timeline.
• Conservative or risk-averse investors should avoid this position, as the investment structure locks in a capital loss on the core shares and offers only an uncertain, high-risk potential return from the CVR.
• For aggressive investors and special situations desks, the key variable to monitor will be any news or disclosures from Sycamore Partners regarding the divestiture process and valuation of the medical clinic business, as this is the sole driver of returns beyond the base offer.
• Existing shareholders must decide whether to hold through the acquisition, thereby accepting the $11.45 cash payment plus the highly speculative CVR, or to exit the position at the current market price to crystallize a more certain return.